<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711436078</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711436078</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Peripheral Arterial Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prevalence, Predictors, and Impact of Peripheral Arterial Disease in Hemodialysis Patients</article-title>
<subtitle>A Cohort Study With a 3-year Follow-Up</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Thani</surname>
<given-names>Hassan Al</given-names>
</name>
<degrees>MB, ChB, FRCS</degrees>
<xref ref-type="aff" rid="aff1-0003319711436078">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711436078"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>Ayman</given-names>
</name>
<degrees>MB, ChB, MSc, FRCP, FACC, FESC</degrees>
<xref ref-type="aff" rid="aff2-0003319711436078">2</xref>
<xref ref-type="aff" rid="aff3-0003319711436078">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hussein</surname>
<given-names>Ahmed</given-names>
</name>
<degrees>MB, ChB</degrees>
<xref ref-type="aff" rid="aff1-0003319711436078">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sadek</surname>
<given-names>Ahmed</given-names>
</name>
<degrees>MB, ChB</degrees>
<xref ref-type="aff" rid="aff1-0003319711436078">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharaf</surname>
<given-names>Ahmed</given-names>
</name>
<degrees>MB, ChB</degrees>
<xref ref-type="aff" rid="aff1-0003319711436078">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>R.</surname>
<given-names>Singh</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-0003319711436078">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koshy</surname>
<given-names>Valsa</given-names>
</name>
<degrees>RN</degrees>
<xref ref-type="aff" rid="aff1-0003319711436078">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suwaidi</surname>
<given-names>Jassim Al</given-names>
</name>
<degrees>MB, ChB, FACC, FSCAI, FESC</degrees>
<xref ref-type="aff" rid="aff2-0003319711436078">2</xref>
<xref ref-type="aff" rid="aff3-0003319711436078">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711436078"><label>1</label>Department of Vascular Surgery, Hamad General Hospital, Doha, Qatar</aff>
<aff id="aff2-0003319711436078"><label>2</label>Department of Cardiology, Hamad General Hospital, Doha, Qatar</aff>
<aff id="aff3-0003319711436078"><label>3</label>Clinical Medicine, Weill Cornell Medical School, Doha, Qatar</aff>
<aff id="aff4-0003319711436078"><label>4</label>Medical Research Center, Doha, Qatar</aff>
<author-notes>
<corresp id="corresp1-0003319711436078">Hassan Al Thani, Department of vascular surgery, HMC, PO Box 3050, Doha, Qatar Email: <email>traumaresearch@hmc.org.qa</email>; <email>althanih@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>2</issue>
<fpage>98</fpage>
<lpage>104</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We evaluated the prevalence, predictors, and outcome of peripheral arterial disease (PAD) among hemodialysis (HD) patients (n = 252) in a prospective study (3-year follow-up) conducted in Qatar. Those with PAD (n = 97; 38.5%) were older and more likely to be males and to have diabetes mellitus, prior coronary artery disease (CAD), or cerebrovascular disease. Diabetic retinopathy was an independent predictor of PAD (adjusted odds ratio: 2.7; <italic>P</italic> = .004). Women had a higher mortality. Three-year all-cause mortality was high in the PAD group (adjusted hazard ratios [HRs] 2.92; 95% confidence interval [CI] 1.55-5.51). Other predictors of mortality were age (HR 1.06; 95% CI 1.04-1.10), number of vascular access (HR 2.3; 95% CI 1.04-5.01), and prior CAD (HR 1.8; 95% CI 1.05-3.49). Prevalence of PAD was high among HD patients. Early detection of PAD as well as diabetic retinopathy is of value in identifying an even higher risk population among HD patients.</p>
</abstract>
<kwd-group>
<kwd>hemodialysis</kwd>
<kwd>peripheral arterial disease</kwd>
<kwd>mortality</kwd>
<kwd>Qatar</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711436078">
<title>Introduction</title>
<p>The prevalence of peripheral arterial disease (PAD) is high worldwide; it affects around 5% of patients aged ≥40 years in the United States.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711436078">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711436078">2</xref>
</sup> The prevalence of PAD increases with older age, non-Caucasian ethnicities and has a negative impact on outcomes.<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436078">2</xref>
<xref ref-type="bibr" rid="bibr3-0003319711436078"/>–<xref ref-type="bibr" rid="bibr4-0003319711436078">4</xref>
</sup> Moreover, patients with chronic kidney disease have ≥2-fold risk of developing PAD.<sup>
<xref ref-type="bibr" rid="bibr4-0003319711436078">4</xref>
<xref ref-type="bibr" rid="bibr5-0003319711436078"/>
<xref ref-type="bibr" rid="bibr6-0003319711436078"/>–<xref ref-type="bibr" rid="bibr7-0003319711436078">7</xref>
</sup> Data from the National Health and Nutrition Examination Survey<sup>
<xref ref-type="bibr" rid="bibr5-0003319711436078">5</xref>
</sup> reported 24% prevalence of PAD among patients older than 40 years old who had creatinine clearance &lt;60 mL/min/1.73m<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436078">2</xref>
</sup>. According to US Renal Data System report, the incidence of clinical PAD in the dialysis<sup>
<xref ref-type="bibr" rid="bibr8-0003319711436078">8</xref>
</sup> population is 15%. To the best of our knowledge, there is no data describing the prevalence of PAD among hemodialysis (HD) patients in the Middle East. Qatar is a small rapidly developing Middle Eastern country characterized with high prevalence of established vascular risk factors.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711436078">9</xref>
<xref ref-type="bibr" rid="bibr10-0003319711436078"/>
<xref ref-type="bibr" rid="bibr11-0003319711436078"/>–<xref ref-type="bibr" rid="bibr12-0003319711436078">12</xref>
</sup> Prevalence of end-stage renal disease (ESRD) in Qatar is 624 patients per million population with an incidence of 202 patients per million population per year.<sup>
<xref ref-type="bibr" rid="bibr13-0003319711436078">13</xref>
</sup> Moreover, in Qatar, the prevalence of diabetic nephropathy, the commonest cause of ESRD, increased<sup>
<xref ref-type="bibr" rid="bibr13-0003319711436078">13</xref>
<xref ref-type="bibr" rid="bibr14-0003319711436078"/>–<xref ref-type="bibr" rid="bibr15-0003319711436078">15</xref>
</sup> from 26% to 48% between 1998 and 2006.</p>
<p>We evaluated the frequency of PAD in non-Caucasian HD patients and identified the predictors of PAD and their 3-year morbidity and mortality.</p>
</sec>
<sec id="section2-0003319711436078" sec-type="methods">
<title>Methods</title>
<p>Data were obtained from a prospective cohort study based on the outpatient HD unit at Hamad Medical Corporation in the state of Qatar in 2007. We enrolled 252 patients who were on regular HD for ESRD regardless of the cause, age, and sex. Exclusion criteria include refusal to participate in the study or to undergo ankle–brachial index (ABI) testing. Patients who were on peritoneal dialysis were excluded. Patients were divided into 2 groups according to whether they had PAD or not based on the clinical assessment and ABI. There was on-site regular follow-up during the HD dialysis sessions for almost 36 months. The study was approved by Institutional Review Board committee.</p>
<p>Patients were considered to have PAD if they had 1 of the following criteria: ABI &lt;0.9, history of intermittent claudication, vascular bypass or endovascular intervention for occlusive vascular disease, or amputation due to occlusive vascular disease. Data were collected by the attending physician using clinical assessment, medical history, baseline demographics, comorbidities, ABI measurement (when applicable), and baseline laboratory test (ie, hemoglobin [Hb], HbA<sub>1c</sub>, serum albumin, parathyroid hormone, calcium, phosphorus, ferritin, vitamin B12, vitamin D, lipid profiles, and serum iron).</p>
<p>The HD-related procedures were reported during the follow-up period and included vascular access (arteriovenous fistula, arteriovenous grafting, and tunneled catheter) and renal transplantation. All patients underwent routine ophthalmologic examination in for detection of retinopathy. The primary end point was all-cause 3-year mortality. Secondary end points included undergoing renal transplant during follow-up or having new vascular events (coronary [acute coronary syndrome], cerebral [transient ischemic attack or stroke], or peripheral [symptoms, ABI &lt; 0.9 or peripheral angiography]).</p>
<sec id="section3-0003319711436078">
<title>Statistical Analysis</title>
<p>Data were presented as proportions or mean ± standard deviation, as appropriate. Baseline demographic characteristics, medical history, clinical presentation, and clinical outcomes were compared between the 2 groups (non-PAD vs PAD). Analyses were conducted using the Student <italic>t</italic> test for continuous variables and Pearson chi-square (χ<sup>
<xref ref-type="bibr" rid="bibr2-0003319711436078">2</xref>
</sup>) test for categorical variables. Natural log transformation of skewed data was carried out. Nonparametric Mann-Whitney <italic>U</italic> test was used to compare duration of HD between the 2 groups. Association between baseline variables (age, sex, diabetes mellitus [DM], duration of DM, diabetic retinopathy, hypertension, smoking, obesity, and dyslipidemia) was performed by logistic regression analysis for detection of the predictors of PAD. Kaplan-Meier curve was constructed to display survival. Univariate and multivariate Cox regression analyses were performed to assess the unadjusted and adjusted hazard ratio (HR) and 95% confidence interval (CI) for the risk of death during the follow-up. Patients were censored at the time of death, renal transplant, or last follow-up. Cox proportional hazards model was used to test the association between PAD and 3-year all-cause mortality after adjusting for the significant covariates (age, sex, DM, educational status, PAD, coronary artery disease [CAD], cerebrovascular disease [CVD], heart failure, number of vascular access, mode of access, and serum calcium). A 2-tailed <italic>P</italic> &lt; .05 was considered significant. Data analysis was carried out using the Statistical Package for Social Sciences version 18 (SPSS Inc, Chicago, Illinois).</p>
</sec>
</sec>
<sec id="section4-0003319711436078">
<title>Results</title>
<p>The mean age of 252 HD patients was 57 ± 15 years. Twenty-seven percent of patients were under age of 50 years (n = 68); 66% of whom were women (n = 45), while in patients &gt;50 years, the majority were men (56%). The most prevalent risk factors were hypertension (84%), DM (57%), smoking (31%), obesity (28%), and dyslipidemia (25%). In those patients, 44% were illiterate, 27% retired, 12% unmarried, and 8% were unemployed. The main causes of ESRD were diabetic nephropathy (52%), primary glomerular disease (11%), vascular nephropathy (9%), and polycystic disease (3.5%). According to ABI measures, 44 (29%) patients had an ABI &lt;0.9, 103 (68%) patients had an ABI 0.9 to 1.3, and only 4 (3%) patients had ABI &gt;1.3.</p>
<sec id="section5-0003319711436078">
<title>Peripheral Arterial Disease Among the HD Population</title>
<p>Diagnosis of PAD was made in 97 patients (38.5%) based on the measurement of ABI &lt;0.9 (45%), presence of minor tissue loss (23%), major amputation (7%), and history of peripheral vascular intervention (angioplasty or bypass surgery; 22%). Polyvascular disease (&gt;1 vascular bed affected) was reported in 10% of patients. The PAD was found in 12.4% of HD patients under age of 50 years. <xref ref-type="table" rid="table1-0003319711436078">Tables 1</xref> and <xref ref-type="table" rid="table2-0003319711436078">2</xref> show the baseline laboratory, demographic, and clinical profiles of HD patients with and without PAD. Compared with non-PAD, patients with PAD were 8 years older and more likely to be men and had higher prevalence DM (77%), diabetic retinopathy, prior CAD, and CVD. Moreover, illiteracy was more prevalent among patients with PAD when compared with non-PAD patients. Prevalence of hypertension, obesity, and dyslipidemia were comparable between the 2 groups, while smoking was more prevalent among non-PAD when compared with patients with PAD. Patients with PAD were more likely to be on oral antiplatelet and insulin therapy. There was no significant differences between the 2 groups regarding baseline mean laboratory values with the exception of lower serum calcium (<italic>P</italic> = .04) and vitamin B12 (<italic>P</italic> = .03) levels among non-PAD when compared with patients with PAD. All patients had low mean values of vitamin D (13 ± 10; reference range = 30-80 ng/mL). <xref ref-type="fig" rid="fig1-0003319711436078">Figure 1</xref> shows the prevalence of PAD in HD patients with different age groups and sex. There was substantial increase in the prevalence of PAD with advancing age. In all age groups, PAD was predominant in men except in patients between 40 and 50 years where 87% were women.</p>
<fig id="fig1-0003319711436078" position="float">
<label>Figure 1.</label>
<caption>
<p>Prevalence of peripheral arterial disease in hemodialysis patients stratified by sex and age groups.</p>
</caption>
<graphic xlink:href="10.1177_0003319711436078-fig1.tif"/>
</fig>
<table-wrap id="table1-0003319711436078" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline Demographics, Risk Factors, Clinical Profiles, and Outcomes in HD Patients With and Without PAD<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0003319711436078" xlink:href="10.1177_0003319711436078-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Non-PAD (n = 155)</th>
<th>PAD (n = 97)</th>
<th>
<italic> P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, years)</td>
<td align="center">54 ± 16</td>
<td align="center">62 ± 12</td>
<td>.001</td>
</tr>
<tr>
<td>Female, %</td>
<td>57</td>
<td>38</td>
<td>.003</td>
</tr>
<tr>
<td>Unmarried, %</td>
<td>12.4</td>
<td>11.6</td>
<td>.84</td>
</tr>
<tr>
<td>Illiterate, %</td>
<td>36</td>
<td>57</td>
<td>.001</td>
</tr>
<tr>
<td>School degree, %</td>
<td>44.5</td>
<td>30</td>
<td>.02</td>
</tr>
<tr>
<td>College degree, %</td>
<td>19.4</td>
<td>13.4</td>
<td>.22</td>
</tr>
<tr>
<td>Unemployed, %</td>
<td>8.4</td>
<td>8.2</td>
<td>.96</td>
</tr>
<tr>
<td>Retired, %</td>
<td>26.5</td>
<td>27.1</td>
<td>.91</td>
</tr>
<tr>
<td colspan="4">Comorbidities and medical history, %</td>
</tr>
<tr>
<td> Diabetes mellitus</td>
<td>48</td>
<td>77</td>
<td>.001</td>
</tr>
<tr>
<td> Retinopathy</td>
<td>34</td>
<td>62</td>
<td>.001</td>
</tr>
<tr>
<td> Diabetic nephropathy</td>
<td>35.5</td>
<td>68</td>
<td>.001</td>
</tr>
<tr>
<td> Coronary artery disease</td>
<td>25</td>
<td>39</td>
<td>.02</td>
</tr>
<tr>
<td> Heart failure</td>
<td>3</td>
<td>8</td>
<td>.04</td>
</tr>
<tr>
<td> Cerebrovascular accidents</td>
<td>5.8</td>
<td>20</td>
<td>.001</td>
</tr>
<tr>
<td> Dyslipidemia</td>
<td>23</td>
<td>30</td>
<td>.19</td>
</tr>
<tr>
<td> Hypertension</td>
<td>83</td>
<td>86</td>
<td>.53</td>
</tr>
<tr>
<td> Smoking</td>
<td>33.5</td>
<td>19.6</td>
<td>.02</td>
</tr>
<tr>
<td> Obesity</td>
<td>32</td>
<td>30</td>
<td>.72</td>
</tr>
<tr>
<td>On oral hypoglycemic %</td>
<td>17.4</td>
<td>16.5</td>
<td>.85</td>
</tr>
<tr>
<td>On insulin therapy %</td>
<td>28.4</td>
<td>55</td>
<td>.001</td>
</tr>
<tr>
<td>Prior antiplatelet use %</td>
<td>50</td>
<td>63</td>
<td>.04</td>
</tr>
<tr>
<td>No. of vascular access &gt;3%</td>
<td>7.1</td>
<td>11.3</td>
<td>.25</td>
</tr>
<tr>
<td>Arteriovenous fistula %</td>
<td>66</td>
<td>62</td>
<td>.48</td>
</tr>
<tr>
<td>permCATH (tunneled access) %</td>
<td>37</td>
<td>49</td>
<td>.07</td>
</tr>
<tr>
<td>Duration of diabetes (mean, years)</td>
<td align="center">16 ± 9</td>
<td>20 ± 8</td>
<td>.05</td>
</tr>
<tr>
<td>Duration of smoking (mean, years)</td>
<td align="center">19 ± 13</td>
<td>20 ± 10</td>
<td>.07</td>
</tr>
<tr>
<td>Duration of HD (months: median, range)</td>
<td align="center">31 (1-314)</td>
<td>26 (2-247)</td>
<td>.19</td>
</tr>
<tr>
<td>LV ejection fraction &lt;50% (%)</td>
<td>40</td>
<td>45</td>
<td>.41</td>
</tr>
<tr>
<td colspan="4">3-Year outcomes (%)</td>
</tr>
<tr>
<td> Renal transplant </td>
<td>9</td>
<td>4</td>
<td>.14</td>
</tr>
<tr>
<td> Myocardial infarction </td>
<td>2.6</td>
<td>5.2</td>
<td>.26</td>
</tr>
<tr>
<td> Cerberovascular accidents </td>
<td>3.2</td>
<td>3.1</td>
<td>.92</td>
</tr>
<tr>
<td> Foot ulcer</td>
<td>4.5</td>
<td>18.6</td>
<td>.001</td>
</tr>
<tr>
<td> Below knee amputation </td>
<td>1.3</td>
<td>6.2</td>
<td>.03</td>
</tr>
<tr>
<td> Above knee amputation </td>
<td>0.6</td>
<td>1.0</td>
<td>.73</td>
</tr>
<tr>
<td> Death </td>
<td>14.2</td>
<td>40.2</td>
<td>.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711436078">
<p>Abbreviations: PAD, peripheral arterial disease; LV, left ventricle; HD, hemodialysis.</p>
</fn>
<fn id="table-fn2-0003319711436078">
<p>
<sup>a</sup> All categorical variables are given in percentage.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0003319711436078" position="float">
<label>Table 2.</label>
<caption>
<p>Baseline Biochemical Findings in Hemodialysis Patients With and Without PAD<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0003319711436078" xlink:href="10.1177_0003319711436078-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Non-PAD (n = 155)</th>
<th>PAD (n = 97)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum parathyroid, pg/mL<sup>b</sup>
</td>
<td>5.6 ± 1.2</td>
<td>5.6 ± 1.03</td>
<td>.19</td>
</tr>
<tr>
<td>Serum calcium, mmol/L</td>
<td>2.07 ± 0.3</td>
<td>2.13 ± 0.2</td>
<td>.04</td>
</tr>
<tr>
<td>Serum vitamin D, ng/mL</td>
<td>13 ± 11</td>
<td>13 ± 7</td>
<td>.91</td>
</tr>
<tr>
<td>Vitamin B12, pmol/L<sup>b</sup>
</td>
<td>5.6 ± 0.6</td>
<td>5.8 ± 0.5</td>
<td>.035</td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>11.2 ± 2</td>
<td>11.5 ± 2</td>
<td>.17</td>
</tr>
<tr>
<td>Hemoglobin A<sub>1c</sub>, %</td>
<td>6.8 ± 1.8</td>
<td>7.2 ± 1.6</td>
<td>.18</td>
</tr>
<tr>
<td>Serum albumin, g/L</td>
<td>37 ± 5</td>
<td>36 ± 5</td>
<td>.50</td>
</tr>
<tr>
<td>Serum ferritin, μg/L<sup>b</sup>
</td>
<td>530 ± 40</td>
<td>558 ± 39</td>
<td>.64</td>
</tr>
<tr>
<td>Serum phosphorus, mmol/L</td>
<td>1.6 ± 0.5</td>
<td>1.5 ± 0.5</td>
<td>.14</td>
</tr>
<tr>
<td>Serum iron, µmol/L</td>
<td>10.7 ± 5.3</td>
<td>10.5 ± 4.7</td>
<td>.76</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>4.11 ± 1.1</td>
<td>4.18 ± 0.96</td>
<td>.61</td>
</tr>
<tr>
<td>Serum triglyceride, mmol/L</td>
<td>1.90 ± 1.3</td>
<td>1.98 ± 1.4</td>
<td>.60</td>
</tr>
<tr>
<td>Low-density lipoprotein, mmol/L</td>
<td>2.24 ± 0.8</td>
<td>2.29 ± 0.8</td>
<td>.62</td>
</tr>
<tr>
<td>High-density lipoprotein, mmol/L</td>
<td>1.07 ± 0.4</td>
<td>1.08 ± 0.2</td>
<td>.90</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319711436078">
<p>Abbreviations: PAD, peripheral arterial disease; SD, standard deviation.</p>
</fn>
<fn id="table-fn4-0003319711436078">
<p>
<sup>a</sup> Continuous variables are presented with mean ± SD.</p>
</fn>
<fn id="table-fn5-0003319711436078">
<p>
<sup>b</sup> Natural log transformation of skewed data.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Number of vascular access for HD were relatively higher in the PAD group (11.3 vs 7.1; <italic>P</italic> = .05). Percentage of tunneled access was nonsignificantly high in the PAD group (49% vs 37%; <italic>P</italic> = .07), whereas arteriovenous fistulas were nonsignificantly high in non-PAD group (66% vs 62%; <italic>P</italic> = .46).</p>
<sec id="section6-0003319711436078">
<title>Predictors for PAD among HD patients</title>
<p>
<xref ref-type="fig" rid="fig2-0003319711436078">Figure 2</xref> shows logistic regression multivariate analysis using stepwise forward method after adjustment for established cardiovascular risk factors, HbA<sub>1c</sub>, and DM complications. Diabetic retinopathy was an independent predictor of PAD (OR 2.7; 95% CI 1.06-5.45).</p>
</sec>
<sec id="section7-0003319711436078">
<title>Three-year outcomes</title>
<p>Overall mortality rate within 3 years was 24.2% among HD patients and was significantly higher among PAD (40%) when compared with non-PAD patients (14.2%). Mortality rate was higher among patients with ABI &lt;0.9 (41%) compared with ABI &gt;1.3 (25%) and ABI 0.9 to 1.3 (14%).</p>
<fig id="fig2-0003319711436078" position="float">
<label>Figure 2.</label>
<caption>
<p>Predictors of peripheral arterial disease among hemodialysis patients.</p>
</caption>
<graphic xlink:href="10.1177_0003319711436078-fig2.tif"/>
</fig>
<p>Women had nonsignificant higher mortality rate when compared with men (with PAD: 43% vs 38%, <italic>P</italic> = .63 and without PAD: 18% vs 9%, <italic>P</italic> = .11). <xref ref-type="fig" rid="fig3-0003319711436078">Figure 3</xref> shows the results of both univariate and multivariate Cox proportional hazards model for predictors of 3-year mortality in HD patients. Univariate analysis shows that compared with their counterparts, patients with PAD had an approximately 4-fold increase in mortality. We developed a multivariable model to adjust for age, sex, DM, educational status, CAD, CVD, heart failure, number of vascular access, mode of access, and serum calcium that might confound the association between PAD and mortality. After adjustment, PAD remained strongly associated with high mortality (HR 2.92; 95% CI 1.55-5.51, <italic>P</italic> = .001). Other predictors for mortality were age (HR 1.06; 95% CI 1.04-1.10, <italic>P</italic> = .001), number of vascular access (HR 2.3; 95% CI 1.55-5.51, <italic>P</italic> = .04), and prior CAD (HR 1.85; 95%CI 1.05-3.49, <italic>P</italic> = .04). <xref ref-type="fig" rid="fig4-0003319711436078">Figure 4</xref> shows the Kaplan-Meier survival curve and adjusted survival and hazard function curves.</p>
<fig id="fig3-0003319711436078" position="float">
<label>Figure 3.</label>
<caption>
<p>Univariate and multivariate Cox proportional hazards model for predictors of 3-year mortality in hemodialysis patients.</p>
</caption>
<graphic xlink:href="10.1177_0003319711436078-fig3.tif"/>
</fig>
<fig id="fig4-0003319711436078" position="float">
<label>Figure 4.</label>
<caption>
<p>Kaplan-Meier survival, adjusted survival, and hazard function curves.</p>
</caption>
<graphic xlink:href="10.1177_0003319711436078-fig4.tif"/>
</fig>
</sec>
<sec id="section8-0003319711436078">
<title>New vascular disease during the study</title>
<p> In all, 8% of HD patients underwent renal transplantation, 29% developed CAD, and 3.4% developed stroke. In the non-PAD group, 11.5% developed PAD, 9% underwent transplantation, and 28% developed CAD. In the PAD group, 23.5% developed CAD and 4% underwent transplantation. Foot ulcers and below knee amputations were 4 to 5 times higher in PAD patients compared with non-PAD group. <xref ref-type="fig" rid="fig1-0003319711436078">Figure 1</xref> shows the percentage of new PAD cases during follow-up in different age groups.</p>
</sec>
</sec>
</sec>
<sec id="section9-0003319711436078">
<title>Discussion</title>
<p>There is no published data from the Middle East evaluating the association between HD and PAD. Mostly the available reports relied on western experiences. The present cohort study has several key findings. It studied this association in an ethnic population that was not evaluated before. Peripheral arterial disease is highly prevalent among HD patients living in Qatar (38.5%). <xref ref-type="table" rid="table3-0003319711436078">Table 3</xref> describes the 6 studies that reported the prevalence of PAD in HD populations.<sup>
<xref ref-type="bibr" rid="bibr16-0003319711436078">16</xref>
<xref ref-type="bibr" rid="bibr17-0003319711436078"/>
<xref ref-type="bibr" rid="bibr18-0003319711436078"/>
<xref ref-type="bibr" rid="bibr19-0003319711436078"/>–<xref ref-type="bibr" rid="bibr20-0003319711436078">20</xref>
</sup> Adragao et al<sup>
<xref ref-type="bibr" rid="bibr20-0003319711436078">20</xref>
</sup> from Portugal and our study showed the highest percentage of PAD; however, our population was 11 years younger. Crude all-cause mortality is high among HD patients (24%) and PAD-HD patients (40%, <italic>P</italic> = .001). The PAD is associated with 3-fold increase in mortality after adjustment for relevant variables in HD patients. Interestingly, diabetic retinopathy was an independent predictor of the presence of PAD among HD patients even after adjustment for other risk factors. This finding was not clearly reported before and needs confirmation. Previous studies demonstrated that diabetic retinopathy is positively associated with mortality and cardiovascular events.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711436078">21</xref>
<xref ref-type="bibr" rid="bibr22-0003319711436078"/>–<xref ref-type="bibr" rid="bibr23-0003319711436078">23</xref>
</sup> This association was explained in part by the presence of certain risk factors and underlying inflammatory pathogenesis.<sup>
<xref ref-type="bibr" rid="bibr22-0003319711436078">22</xref>,<xref ref-type="bibr" rid="bibr24-0003319711436078">24</xref>
</sup> Consistent with our finding, O’Hare et al concluded that this association was independent of current smoking, hypertension, dyslipidemia, glycemic control, and duration of DM.<sup>
<xref ref-type="bibr" rid="bibr25-0003319711436078">25</xref>
</sup> This may suggest the presence of common background pathways for diabetic microvascular and macrovascular disease other than those included in the cardiovascular risk assessment.<sup>
<xref ref-type="bibr" rid="bibr25-0003319711436078">25</xref>
</sup> Our study shows poor glycemic control (HbA<sub>1c</sub> 7.5 ± 1.8 vs 6.2 ± 1.4, <italic>P</italic> = .001) and high prevalence of dyslipidemia (38% vs 15%, <italic>P</italic> = .001) in patients with diabetic retinopathy. Although there is a high prevalence of DM in Qatar, the incidence of ABI &gt;1.3 (noncompressible vessels) was low (3%). The morality rate was higher in patients with low and high ABI compared with normal ABI. This U-shaped relationship between ABI values and mortality was consistent with previous studies and still not fully explained by the increased occurrence of diabetes, hypertension, and renal disease.<sup>
<xref ref-type="bibr" rid="bibr26-0003319711436078">26</xref>
</sup>
</p>
<table-wrap id="table3-0003319711436078" position="float">
<label>Table 3.</label>
<caption>
<p>Studies Evaluated Peripheral Arterial Disease in Hemodialysis Patients</p>
</caption>
<graphic alternate-form-of="table3-0003319711436078" xlink:href="10.1177_0003319711436078-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Rajagopalan et al<sup>
<xref ref-type="bibr" rid="bibr16-0003319711436078">16</xref>
</sup>
</th>
<th>Ono et al<sup>
<xref ref-type="bibr" rid="bibr17-0003319711436078">17</xref>
</sup>
</th>
<th>Chen et al<sup>
<xref ref-type="bibr" rid="bibr18-0003319711436078">18</xref>
</sup>
</th>
<th>Ogata et al<sup>
<xref ref-type="bibr" rid="bibr19-0003319711436078">19</xref>
</sup>
</th>
<th>Adragao et al<sup>
<xref ref-type="bibr" rid="bibr20-0003319711436078">20</xref>
</sup>
</th>
<th>Current Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication year </td>
<td>2006</td>
<td>2003</td>
<td>2009</td>
<td>2010</td>
<td>2011</td>
<td>2011</td>
</tr>
<tr>
<td>Number of HD patients </td>
<td>29 873</td>
<td>1010</td>
<td>225</td>
<td>315</td>
<td>219</td>
<td>252</td>
</tr>
<tr>
<td>Design</td>
<td align="center">Retrospective, multinational</td>
<td align="center">Prospective</td>
<td align="center">Prospective</td>
<td align="center">Cross-sectional cohort</td>
<td align="center">Prospective</td>
<td align="center">Prospective</td>
</tr>
<tr>
<td>Age (mean)</td>
<td>66</td>
<td>65</td>
<td>67</td>
<td>61</td>
<td>69</td>
<td>57</td>
</tr>
<tr>
<td>Men, %</td>
<td>58</td>
<td>63.5</td>
<td>43.5</td>
<td>67.3</td>
<td>60</td>
<td>50</td>
</tr>
<tr>
<td>Diabetes mellitus </td>
<td>38%</td>
<td>34%</td>
<td>41%</td>
<td>31%</td>
<td>20%</td>
<td>57%</td>
</tr>
<tr>
<td>PAD, %</td>
<td>25.3</td>
<td>16.5</td>
<td>15.5</td>
<td>23.8</td>
<td>41</td>
<td>38.5</td>
</tr>
<tr>
<td>Percentage of PAD in diabetics</td>
<td>59%</td>
<td>62%</td>
<td>69%</td>
<td>59.5%</td>
<td>22%</td>
<td>71%</td>
</tr>
<tr>
<td>Follow-up (mean, months)</td>
<td>18</td>
<td>22.3</td>
<td>42</td>
<td>-</td>
<td>28.9</td>
<td>36</td>
</tr>
<tr>
<td>Diagnosis of PAD</td>
<td align="center">History and clinically</td>
<td align="center">ABI</td>
<td align="center">ABI</td>
<td align="center">ABI and BA pulse wave velocity</td>
<td align="center">ABI and vascular calcification</td>
<td align="center">ABI and clinical</td>
</tr>
<tr>
<td>PAD and all-cause mortality </td>
<td align="center">HR (1.36, <italic>P</italic> &lt; .001)</td>
<td align="center">Adjusted HR (4.04, <italic>P</italic> &lt; .001)</td>
<td align="center">N/A</td>
<td align="center">N/A</td>
<td align="center">Adjusted HR (3.9, <italic>P</italic> &lt; .001)</td>
<td align="center">Adjusted HR (2.9, <italic>P</italic> = .001)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0003319711436078">
<p>Abbreviations: HD, hemodialysis; PAD, peripheral arterial disease; HR, hazard ratio; ABI, ankle–brachial index; BA, brachial–ankle; N/A, not available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There is substantial increase in both the incidence and prevalence of PAD with increasing age. The prevalence of PAD is slightly greater in men than women, particularly in the younger age groups.<sup>
<xref ref-type="bibr" rid="bibr15-0003319711436078">15</xref>
</sup> Our study shows a significant increase in PAD among women compared with men aged between 40 and 50 years, otherwise, male gender was dominant in the other age groups. The presence of PAD increases mortality in women from 18% to 43% (<italic>P</italic> = .003).</p>
<p>During follow-up, 11.5% of the non-PAD group developed PAD; this finding might reflect the progression of atherosclerosis in this high-risk population. The number of new PAD cases increased after age of 40 (5.3%) and reached 16% in patients with age &gt;60 years. Previous study showed that renal insufficiency is independently associated with future PAD events among postmenopausal women.<sup>
<xref ref-type="bibr" rid="bibr27-0003319711436078">27</xref>
</sup> Furthermore, PAD is highly prevalent among dialysis patients with high amputation rates in this group.<sup>
<xref ref-type="bibr" rid="bibr5-0003319711436078">5</xref>,<xref ref-type="bibr" rid="bibr6-0003319711436078">6</xref>
</sup> The amputation rate in our study was 4 times greater in the PAD-HD compared with non-PAD-HD patients (12% vs 3.2%). Moreover, the present study reported that 9% of non-PAD patients underwent renal transplantation versus 4% in the PAD group; these findings may reflect the high-risk pattern of the latter group.</p>
<p>Number of vascular accesses and percentage of tunneled access were relatively high in the PAD group, while the percentage of arteriovenous fistula was high in the non-PAD group. Chen et al reported that ABI &lt; 0.9 is significantly correlated with increased vascular access failure.<sup>
<xref ref-type="bibr" rid="bibr18-0003319711436078">18</xref>
</sup> Therefore, screening for PAD in HD patients is important to identify a high-risk group for access failure and then to guide decisions for the optimal access. In the current study, the number of vascular accesses was independent predictor of all-cause mortality; this might be in part related to sepsis or interruption of some HD sessions.</p>
<p>One limitation is that the current study could not define the cause of death [Cardiovascular (CV) vs non-CV] in all cases. The relatively small number of patients of the subgroups (eg, men vs women, DM vs no DM, and PAD vs non-PAD) is another limitation. Notably, patients with noncompressible vessels due to calcification in DM and ESRD were few in our population.</p>
<p>In conclusion, this study reports high prevalence of PAD among HD patients in the Middle East. Diabetic retinopathy is an independent predictor of PAD among these patients. Moreover, PAD and number of vascular access procedures are independent predictors of long-term mortality. Primary prevention and early detection of PAD and diabetic retinopathy are important in HD population. Even earlier than that we should prevent kidney failure.<sup>
<xref ref-type="bibr" rid="bibr28-0003319711436078">28</xref>,<xref ref-type="bibr" rid="bibr29-0003319711436078">29</xref>
</sup>
</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the patients, staff of the HD unit, and the section of vascular surgery at Hamad General Hospital. All authors read and approved the manuscript with no conflict of interest. The study was presented in part at the Mayo Clinic International Vascular Symposium in Paris, France (September 9-11, 2011).</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711436078">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711436078">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711436078">
<label>1</label>
<citation citation-type="journal">
<collab collab-type="author">Centers for Disease Control and Prevention (CDC)</collab>: <article-title>Lower extremity disease among persons aged &gt;40 years with and without diabetes—United States, 1999-2002</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2005</year>;<volume>54</volume>(<issue>45</issue>):<fpage>1158</fpage>–<lpage>1160</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711436078">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeLoach</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Mohler</surname>
<given-names>ER</given-names>
<suffix> 3rd</suffix>
</name>
</person-group>. <article-title>Peripheral arterial disease: a guide for nephrologists</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2007</year>;<volume>2</volume>(<issue>4</issue>):<fpage>839</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711436078">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liew</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Bartholomew</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Demirjian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Michaels</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>MJ</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2008</year>;<volume>3</volume>(<issue>4</issue>):<fpage>1084</fpage>–<lpage>1089</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711436078">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norgren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hiatt</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Dormandy</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Inter-society consensus for the management of peripheral arterial disease (TASC II)</article-title>. <source>Eur J Vasc Endovasc Surg</source>. <year>2007</year>;<volume>33</volume>(<issue>suppl 1</issue>): <fpage>S1</fpage>–<lpage>S75</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711436078">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Hare</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Glidden</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>CY</given-names>
</name>
</person-group>. <article-title>High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the national health and nutrition examination survey</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>3</issue>):<fpage>320</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711436078">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Hare</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Lower-extremity peripheral arterial disease among patients with end-stage renal disease</article-title>. <source>J Am Soc Nephrol</source>. <year>2001</year>;<volume>12</volume>(<issue>12</issue>):<fpage>2838</fpage>–<lpage>2847</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711436078">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eggers</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Gohdes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pugh</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population</article-title>. <source>Kidney Int</source>. <year>1999</year>;<volume>56</volume>(<issue>4</issue>):<fpage>1524</fpage>–<lpage>1533</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711436078">
<label>8</label>
<citation citation-type="book">
<collab collab-type="author">National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney Urologic and Hematologic Diseases</collab>. <article-title>Patients characteristics. In: United States Renal Data System, USRDS 2000 annual data report</article-title>, <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney Urologic and Hematologic Diseases</publisher-name>; <year>2000</year>, <fpage>339</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711436078">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zubaid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shehab</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the Middle East</article-title>. <source>Clin Cardiol</source>. <year>2011</year>;<volume>34</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711436078">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zubaid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sulaiman</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a Registry of 8176 patients</article-title>. <source>Mayo Clin Proc</source>. <year>2010</year>;<volume>85</volume>(<issue>4</issue>):<fpage>332</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711436078">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Albinali</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Bener</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Al Suwaidi</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Prevalence and impact of diabetes mellitus in patients with acute myocardial infarction: a 10-year experience</article-title>. <source>Angiology</source>. <year>2009</year> <comment>Dec-2010</comment>;<volume>60</volume>(<issue>6</issue>):<fpage>683</fpage>–<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711436078">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rashdan</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Ankle-brachial index and extent of atherosclerosis in patients from the Middle East (the AGATHA-ME study): a cross-sectional multicenter study</article-title>. <source>Angiology</source>. <year>2009</year>;<volume>60</volume>(<issue>3</issue>):<fpage>329</fpage>–<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711436078">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shigidi</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Ramachandiran</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rashed</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Fituri</surname>
<given-names>OM</given-names>
</name>
</person-group>. <article-title>Demographic data and hemodialysis population dynamics in Qatar: A five year survey</article-title>. <source>Saudi J Kidney Dis Transpl</source>. <year>2009</year>;<volume>20</volume>(<issue>3</issue>):<fpage>493</fpage>–<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711436078">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abboud</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Incidence, prevalence, and treatment of end-stage renal disease in the Middle East</article-title>. <source>Ethn Dis</source>. <year>2006</year>;<volume>16</volume>(<issue>2 suppl 2</issue>): <fpage>S2</fpage>–<lpage>2</lpage>-4.</citation>
</ref>
<ref id="bibr15-0003319711436078">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rashed</surname>
<given-names>A</given-names>
</name>
</person-group>, <article-title>Aboud O. Renal transplantation: seventeen years of follow-up in Qatar</article-title>.<source>Transplant Proc</source>. <year>2004</year>;<volume>36</volume>(<issue>6</issue>):<fpage>1835</fpage>–<lpage>1838</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711436078">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajagopalan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dellegrottaglie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Furniss</surname>
<given-names>AL</given-names>
</name>
<etal/>
</person-group>. <article-title>Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>(<issue>18</issue>):<fpage>1914</fpage>–<lpage>1922</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711436078">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsuchida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients</article-title>. <source>J Am Soc Nephrol</source>. <year>2003</year>;<volume>14</volume>(<issue>6</issue>):<fpage>1591</fpage>–<lpage>1598</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711436078">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2009</year>;<volume>4</volume>(<issue>1</issue>):<fpage>128</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711436078">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kumata-Maeta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shishido</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Detection of peripheral artery disease by duplex ultrasonography among hemodialysis patients</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2010</year>;<volume>5</volume>(<issue>12</issue>):<fpage>2199</fpage>–<lpage>2206</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711436078">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adragao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pires</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Branco</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Ankle--brachial index, vascular calcifications and mortality in dialysis patients</article-title>. <source>Nephrol Dial Transplant</source>. <year>2012</year>;<volume>27</volume>(<issue>1</issue>):<fpage>318</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711436078">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Kuller</surname>
<given-names>LH</given-names>
</name>
<etal/>
</person-group>. <article-title>The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the cardiovascular health study</article-title>. <source>Br J Ophthalmol</source>. <year>2002</year>;<volume>86</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711436078">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Hecke</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Stehouwer</surname>
<given-names>CD</given-names>
</name>
<etal/>
</person-group>. <article-title>EURODIAB prospective complications study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>(<issue>6</issue>):<fpage>1383</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711436078">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Canani</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Azevedo</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies</article-title>. <source>Diabetes Care</source>. <year>2011</year>;<volume>34</volume>(<issue>5</issue>):<fpage>1238</fpage>–<lpage>1244</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711436078">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>TY</given-names>
</name>
</person-group>. <article-title>Diabetic retinopathy</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>(<issue>9735</issue>):<fpage>124</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711436078">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juutilainen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lehto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rönnemaa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pyörälä</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Laakso</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women</article-title>. <source>Diabetes Care</source>. <year>2007</year>;<volume>30</volume>
<issue>(2)</issue>:<fpage>292</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711436078">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resnick</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Devereux</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Fabsitz</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>BV</given-names>
</name>
</person-group>. <article-title>Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>6</issue>):<fpage>733</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711436078">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Hare</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Vittinghoff</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hsia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shlipak</surname>
<given-names>MG</given-names>
</name>
</person-group>. <article-title>Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS)</article-title>. <source>J Am Soc Nephrol</source>. <year>2004</year>;<volume>15</volume>(<issue>4</issue>):<fpage>1046</fpage>–<lpage>1051</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711436078">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Mitsiou</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Tziomalos</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy</article-title>. <source>Expert Opin Pharmacother</source>. <year>2010</year>;<volume>11</volume>(<issue>5</issue>):<fpage>723</fpage>–<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711436078">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paraskevas</surname>
<given-names>KI</given-names>
</name>
<name>
<surname>Kotsikoris</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Koupidis</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Tzovaras</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention</article-title>. <source>Int Urol Nephrol</source>. <year>2010</year>;<volume>42</volume>(<issue>4</issue>):<fpage>999</fpage>–<lpage>1006</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>